STOCK TITAN

[Form 4] HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Heron Therapeutics (HRTX) reported an insider equity change. EVP & Chief Development Officer William P. Forbes acquired 3,874 shares of common stock on 10/19/2025 via the conversion of restricted stock units (transaction code M). Following this event, he directly owns 154,509 shares of common stock. The filing also lists 34,869 derivative securities remaining as restricted stock units. Each RSU equals one share, and the RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.

Heron Therapeutics (HRTX) ha riportato una modifica nell'equità degli insider. Il vicepresidente esecutivo e Chief Development Officer William P. Forbes ha acquisito 3.874 azioni ordinarie il 19/10/2025 tramite la conversione di unità di azioni vincolate (codice di transazione M). Dopo questo evento, possiede direttamente 154.509 azioni ordinarie. La documentazione elenca anche 34.869 strumenti derivati rimanenti come unità di azioni vincolate. Ogni RSU corrisponde a una azione, e le RSU vestono in 16 rate trimestrali uguali a partire dal 19/01/2024.

Heron Therapeutics (HRTX) informó un cambio de acciones de insiders. William P. Forbes, vicepresidente ejecutivo y Director de Desarrollo, adquirió 3.874 acciones ordinarias el 19/10/2025 mediante la conversión de unidades de acciones restringidas (código de transacción M). Tras este evento, posee directamente 154.509 acciones ordinarias. La presentación también enumera 34.869 valores derivados restantes como unidades de acciones restringidas. Cada RSU equivale a una acción, y las RSU se consolidan en 16 cuotas trimestrales iguales que comienzan un trimestre después del 19/01/2024.

헤론 테라퓨티스(HRTX)는 내부자 주식 변경을 보고했습니다. EVP 겸 개발 책임자 William P. Forbes는 2025년 10월 19일에 제한 주식단위(RSU) 전환을 통해 3,874주의 보통주를 취득했습니다(거래 코드 M). 이 사건 이후 그는 직접 154,509주의 보통주를 소유합니다. 제출 문서에는 남아 있는 파생 증권 34,869주가 RSU로 남아 있음을 명시합니다. 각 RSU는 한 주에 해당하며 RSU는 2024년 1월 19일의 직후 시작하여 16개의 동일한 분기별 지급으로 vest됩니다.

Heron Therapeutics (HRTX) a annoncé un changement d'actions détenues par des initiés. William P. Forbes, vice-président exécutif et directeur du développement, a acquis 3 874 actions ordinaires le 19/10/2025 via la conversion d'unités d'actions restreintes (code de transaction M). Suite à cet événement, il détient directement 154 509 actions ordinaires. Le dossier répertorie également 34 869 titres dérivés restants sous forme d'unités d'actions restreintes. Chaque RSU équivaut à une action, et les RSU se libèrent en 16 versements trimestriels égaux à partir du premier trimestre suivant le 19/01/2024.

Heron Therapeutics (HRTX) meldete eine Insider-Aktienänderung. EVP und Chief Development Officer William P. Forbes kaufte am 19.10.2025 3.874 Stammaktien durch die Umwandlung von Restricted Stock Units (Transaktionscode M). Nach dieser Veranstaltung besitzt er direkt 154.509 Stammaktien. Die Einreichung listet außerdem 34.869 Derivatwerte als verbleibende RSUs auf. Jede RSU entspricht einer Aktie, und die RSUs vesten in 16 gleichen vierteljährlichen Raten, beginnend im ersten Quartal nach dem 19.01.2024.

Heron Therapeutics (HRTX) أبلغت عن تغيير في حقوق المساهمين من الداخل. اشترى ويليام ب. فوربس، نائب الرئيس التنفيذي والمدير التنفيذي للشؤون التطويرية، 3,874 سهماً عاديّاً في 19/10/2025 عبر تحويل وحدات الأسهم المقيدة (رمز الصفقة M). بعد هذا الحدث، أصبح يمتلك مباشرة 154,509 سهماً عاديّاً. كما تُدرج الوثيقة 34,869 أداة مالية derivatives كـ وحدات الأسهم المقيدة المتبقية. كل RSU يساوي سهماً واحداً، وتتكتل RSUs في 16 دفعة ربع سنوية متساوية بدءاً من الربع الذي يلي 19/01/2024.

Heron Therapeutics (HRTX) 报告了内幕交易相关股权变动。执行副总裁兼首席开发官 William P. Forbes 于 2025/10/19 通过将受限股票单位(交易代码 M)转化为普通股,购买了 3,874 股普通股。事件发生后,他直接持有 154,509 股普通股。申报文件还列出剩余 34,869 只派生证券作为受限股票单位。每个 RSU 等于一股,RSU 将在自 2024/01/19 起的第一个季度开始分 16 期等额归属。

Positive
  • None.
Negative
  • None.

Heron Therapeutics (HRTX) ha riportato una modifica nell'equità degli insider. Il vicepresidente esecutivo e Chief Development Officer William P. Forbes ha acquisito 3.874 azioni ordinarie il 19/10/2025 tramite la conversione di unità di azioni vincolate (codice di transazione M). Dopo questo evento, possiede direttamente 154.509 azioni ordinarie. La documentazione elenca anche 34.869 strumenti derivati rimanenti come unità di azioni vincolate. Ogni RSU corrisponde a una azione, e le RSU vestono in 16 rate trimestrali uguali a partire dal 19/01/2024.

Heron Therapeutics (HRTX) informó un cambio de acciones de insiders. William P. Forbes, vicepresidente ejecutivo y Director de Desarrollo, adquirió 3.874 acciones ordinarias el 19/10/2025 mediante la conversión de unidades de acciones restringidas (código de transacción M). Tras este evento, posee directamente 154.509 acciones ordinarias. La presentación también enumera 34.869 valores derivados restantes como unidades de acciones restringidas. Cada RSU equivale a una acción, y las RSU se consolidan en 16 cuotas trimestrales iguales que comienzan un trimestre después del 19/01/2024.

헤론 테라퓨티스(HRTX)는 내부자 주식 변경을 보고했습니다. EVP 겸 개발 책임자 William P. Forbes는 2025년 10월 19일에 제한 주식단위(RSU) 전환을 통해 3,874주의 보통주를 취득했습니다(거래 코드 M). 이 사건 이후 그는 직접 154,509주의 보통주를 소유합니다. 제출 문서에는 남아 있는 파생 증권 34,869주가 RSU로 남아 있음을 명시합니다. 각 RSU는 한 주에 해당하며 RSU는 2024년 1월 19일의 직후 시작하여 16개의 동일한 분기별 지급으로 vest됩니다.

Heron Therapeutics (HRTX) a annoncé un changement d'actions détenues par des initiés. William P. Forbes, vice-président exécutif et directeur du développement, a acquis 3 874 actions ordinaires le 19/10/2025 via la conversion d'unités d'actions restreintes (code de transaction M). Suite à cet événement, il détient directement 154 509 actions ordinaires. Le dossier répertorie également 34 869 titres dérivés restants sous forme d'unités d'actions restreintes. Chaque RSU équivaut à une action, et les RSU se libèrent en 16 versements trimestriels égaux à partir du premier trimestre suivant le 19/01/2024.

Heron Therapeutics (HRTX) meldete eine Insider-Aktienänderung. EVP und Chief Development Officer William P. Forbes kaufte am 19.10.2025 3.874 Stammaktien durch die Umwandlung von Restricted Stock Units (Transaktionscode M). Nach dieser Veranstaltung besitzt er direkt 154.509 Stammaktien. Die Einreichung listet außerdem 34.869 Derivatwerte als verbleibende RSUs auf. Jede RSU entspricht einer Aktie, und die RSUs vesten in 16 gleichen vierteljährlichen Raten, beginnend im ersten Quartal nach dem 19.01.2024.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Forbes William P

(Last) (First) (Middle)
100 REGENCY FOREST DRIVE
SUITE 300

(Street)
CARY NC 27518

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Development Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/19/2025 M 3,874 A (1) 154,509 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0.00 10/19/2025 M 3,874 (2) (2) Common Stock 3,874 $0.00 34,869 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).
/s/ Kathryn Lester Attorney-in-Fact for William P. Forbes 10/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did HRTX report?

EVP & CDO William P. Forbes acquired 3,874 common shares on 10/19/2025 through RSU conversion (code M).

How many HRTX shares does William P. Forbes own after the transaction?

He directly owns 154,509 shares following the reported transaction.

Were any HRTX shares sold in this filing?

No sales were reported; the transaction reflects RSU conversion to 3,874 common shares.

What RSUs remain for William P. Forbes at HRTX?

The filing shows 34,869 derivative securities remaining as restricted stock units.

How do the HRTX RSUs vest for this grant?

They vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.

What does transaction code M mean in this context?

Code M indicates a conversion of a derivative security, here RSUs converting into common shares at $0.00 per unit.
Heron Therapeutics Inc

NASDAQ:HRTX

HRTX Rankings

HRTX Latest News

HRTX Latest SEC Filings

HRTX Stock Data

247.47M
179.97M
0.74%
87.88%
21.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO